SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AutoImmune-AIMM
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: kathleen who wrote (198)8/8/1997 7:32:00 AM
From: Dr. John M. de Castro   of 298
 
AIMM suggested that the critical variable was gender. That males receive benefit from MYLORAL while females do not. They said that they thought the difference between the DR2- and DR2+ groups in the Phase II and Phase III studies might be due to the small sample size in the Phase II study. However, the result was statistically significant. Which means that it is unlikely to have been a chance event, regardless of sample size. The statistic takes sample size into consideration.

So, there is simply no good explanation for it. It is probably a moot issue, in any case, since I doubt anyone will be pursuing it.

John de C
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News